SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ceftolozane / Tazobactam Injection Formula-
tion

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Ceftolozane / Tazobactam Injection Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD
              Kilsheelan
              Clonmel Tipperary, IE
   Telephone : 353-51-601000
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   +1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

   Classification (REGULATION (EC) No 1272/2008)
   Respiratory sensitisation, Category 1
   H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
   Specific target organ toxicity - repeated exposure, Category 2
   H373: May cause damage to organs through prolonged or repeated exposure.
   Short-term (acute) aquatic hazard, Category 1
   H400: Very toxic to aquatic life.
   Long-term (chronic) aquatic hazard, Category 1
   H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms : 
   Signal word : Danger
   Hazard statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
                       H373 May cause damage to organs through prolonged or
Hazardous components which must be listed on the label:
Ceftolozane
Tazobactam

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No. EC-No. Index-No. Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceftolozane</td>
<td>689293-68-3</td>
<td>Resp. Sens. 1B; H334 STOT RE 2; H373 (Kidney) Aquatic Acute 1; H400</td>
<td>&gt;= 30 - &lt; 50</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET  
according to Regulation (EC) No. 1907/2006

Ceftolozane / Tazobactam Injection Formulation

Version 4.4  
Revision Date: 12.10.2021  
SDS Number: 441472-00015  
Date of last issue: 23.03.2020  
Date of first issue: 06.01.2016

<table>
<thead>
<tr>
<th>Aquatic Chronic</th>
<th>M-Factor (Acute aquatic toxicity): 10</th>
<th>M-Factor (Chronic aquatic toxicity): 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tazobactam</td>
<td>89786-04-9</td>
<td>&gt; = 10 - &lt; 20</td>
</tr>
<tr>
<td></td>
<td>Resp. Sens. 1B; H334</td>
<td></td>
</tr>
<tr>
<td></td>
<td>STOT RE 2; H373 (Liver)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aquatic Acute 1; H400</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aquatic Chronic 2; H411</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M-Factor (Acute aquatic toxicity): 1</td>
<td></td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water.
Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.
Ceftolozane / Tazobactam Injection Formula-
tion

4.2 Most important symptoms and effects, both acute and delayed

Risks: May cause allergy or asthma symptoms or breathing difficul-
ties if inhaled.
May cause damage to organs through prolonged or repeated exposure.
Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-
ucts: Carbon oxides
Metal oxides
Chlorine compounds
Nitrogen oxides (NOx)

5.3 Advice for firefighters

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circum-
cumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed.
Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitisers. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceftolozane</td>
<td>689293-68-3</td>
<td>TWA</td>
<td>1000 µg/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td>Tazobactam</td>
<td>89786-04-9</td>
<td>TWA</td>
<td>250 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium chloride</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>2068.62 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Acute systemic effects</td>
<td>2068.62 mg/m³</td>
</tr>
</tbody>
</table>
Ceftolozane / Tazobactam Injection Formula-
tion

<table>
<thead>
<tr>
<th>Workers</th>
<th>Skin contact</th>
<th>Long-term systemic effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>295.52 mg/kg bw/day</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Consumers</th>
<th>Inhalation</th>
<th>Long-term systemic effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>443.28 mg/m³</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Consumers</th>
<th>Skin contact</th>
<th>Long-term systemic effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>126.65 mg/kg bw/day</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Consumers</th>
<th>Ingestion</th>
<th>Long-term systemic effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>126.65 mg/kg bw/day</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>L-Arginine hydrochloride</th>
<th>Workers</th>
<th>Inhalation</th>
<th>Long-term systemic effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>668.2 mg/m³</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Skin contact</th>
<th>Long-term systemic effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>947.5 mg/kg bw/day</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Consumers</th>
<th>Inhalation</th>
<th>Long-term systemic effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>164.8 mg/m³</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Consumers</th>
<th>Skin contact</th>
<th>Long-term systemic effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>473.8 mg/kg bw/day</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Consumers</th>
<th>Ingestion</th>
<th>Long-term systemic effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>47.8 mg/kg bw/day</td>
</tr>
</tbody>
</table>

**Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:**

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium chloride</td>
<td>Fresh water</td>
<td>5 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>500 mg/l</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>4.86 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>L-Arginine hydrochloride</td>
<td>Fresh water</td>
<td>2.2 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.22 mg/l</td>
</tr>
<tr>
<td></td>
<td>Intermittent use/release</td>
<td>22 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>12000 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>4.437 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>0.444 mg/kg</td>
</tr>
</tbody>
</table>

**8.2 Exposure controls**

**Engineering measures**
Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

**Personal protective equipment**

**Eye protection**
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or
Hand protection
Material: Chemical-resistant gloves

Skin and body protection
Work uniform or laboratory coat.

Respiratory protection
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to EN 143.
Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state: powder
Colour: No data available
Odour: No data available
Odour Threshold: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Flash point: Not applicable
Auto-ignition temperature: No data available
Decomposition temperature: No data available
pH: No data available
Viscosity
Viscosity, kinematic: No data available
Solubility(ies)
Water solubility: No data available
Partition coefficient: n-octanol/water: No data available
Vapour pressure: No data available
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ceftolozane / Tazobactam Injection Formula-
tion

Version 4.4  Revision Date: 12.10.2021  SDS Number: 441472-00015  Date of last issue: 23.03.2020
Date of first issue: 06.01.2016

Relative density: No data available
Density: No data available
Relative vapour density: No data available
Particle characteristics:
  Particle size: No data available

9.2 Other information
Explosives: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Evaporation rate: No data available
Molecular weight: No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
  Not classified as a reactivity hazard.

10.2 Chemical stability
  Stable under normal conditions.

10.3 Possibility of hazardous reactions
  Hazardous reactions: May form explosive dust-air mixture during processing, han-
  dling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
  Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
  Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
  No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
  Information on likely routes of exposure:
  Inhalation
  Skin contact
  Ingestion
  Eye contact
Acute toxicity
Not classified based on available information.

**Components:**

**Ceftolozane:**
Acute toxicity (other routes of administration):
- LD50 (Rat): > 2.000 mg/kg
  Application Route: Intravenous
- LD50 (Mouse): > 1.500 mg/kg
  Application Route: Intravenous
- LD50 (Dog): > 2.000 mg/kg
  Application Route: Intravenous

**Tazobactam:**
Acute oral toxicity:
- LD50 (Rat): > 5.000 mg/kg
  LD50 (Mouse): > 5.000 mg/kg

Acute toxicity (other routes of administration):
- LD50 (Rat): > 5.000 mg/kg
  Application Route: Intravenous
- LD50 (Mouse): > 5.000 mg/kg
  Application Route: Intravenous
- LD50 (Dog): > 5.000 mg/kg
  Application Route: Intravenous

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Components:**

**Ceftolozane:**
- Test Type: Maximisation Test
- Species: Guinea pig
- Result: Sensitiser

**Tazobactam:**
- Result: Sensitiser
Germ cell mutagenicity
Not classified based on available information.

Components:

Ceftolozane:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: positive

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Result: negative

Test Type: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo
Species: Mouse
Result: negative

Tazobactam:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: mouse lymphoma cells
Result: positive

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster fibroblasts
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Test Type: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo
Species: Mouse
Result: negative
Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Not classified based on available information.

Components:

Ceftolozane:
Effects on fertility:
- Test Type: Fertility/early embryonic development
  - Species: Rat
  - Application Route: Intravenous injection
  - Fertility: NOAEL: 1.000 mg/kg body weight
  - Result: No effects on fertility

Effects on foetal development:
- Test Type: Embryo-foetal development
  - Species: Mouse
  - Application Route: Intravenous injection
  - Developmental Toxicity: NOAEL: 2.000 mg/kg body weight
  - Remarks: No significant adverse effects were reported

  Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Intravenous injection
  - Developmental Toxicity: NOAEL: 1.000 mg/kg body weight
  - Remarks: No significant adverse effects were reported

Tazobactam:
Effects on fertility:
- Test Type: Fertility/early embryonic development
  - Species: Rat
  - Application Route: Intraperitoneal injection
  - Fertility: NOAEL: 640 mg/kg body weight

Effects on foetal development:
- Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Intraperitoneal injection
  - Developmental Toxicity: NOAEL: 40 mg/kg body weight
  - Result: Effects on early embryonic development

  Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Intravenous injection
  - Developmental Toxicity: NOAEL: 3.000 mg/kg body weight
  - Result: No effects on foetal development

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.
Ceftolozane / Tazobactam Injection Formula-
tion

Components:

Ceftolozane:
Target Organs : Kidney
Assessment : May cause damage to organs through prolonged or repeated exposure.

Tazobactam:
Target Organs : Liver
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Ceftolozane:
Species : Rat
NOAEL : 1,000 mg/kg
Application Route : Intravenous
Exposure time : 28 days
Target Organs : Kidney
Symptoms : No adverse effects

Species : Dog
LOAEL : 300 mg/kg
Exposure time : 28 days
Target Organs : Kidney

Tazobactam:
Species : Rat
NOAEL : 40 mg/kg
Application Route : Intraperitoneal
Exposure time : 6 Months
Target Organs : Liver

Species : Dog
NOAEL : 40 mg/kg
LOAEL : 80 mg/kg
Application Route : Intraperitoneal
Exposure time : 6 Months
Target Organs : Liver

Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Ceftolozane:
Ingestion:
Symptoms: Diarrhoea, Fever, Headache, Nausea, Skin irritation, Gastrointestinal discomfort

Tazobactam:
Inhalation:
Remarks: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

SECTION 12: Ecological information

12.1 Toxicity

Components:

Ceftolozane:
Toxicity to algae/aquatic plants:
EC50 (Anabaena flos-aquae): 0.0401 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 0.0018 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity):
10

Toxicity to microorganisms:
EC50: > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 560 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity):
NOEC: 10 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other:
NOEC: 9.6 mg/l
### aquatic invertebrates (Chronic toxicity)

- **Exposure time:** 21 d  
- **Species:** Daphnia magna (Water flea)  
- **Method:** OECD Test Guideline 211

### M-Factor (Chronic aquatic toxicity)

- **M-Factor:** 10

### Tazobactam:

#### Toxicity to algae/aquatic plants

- **EC50 (Anabaena flos-aquae):** 0.96 mg/l  
- **Exposure time:** 72 h  
- **Method:** OECD Test Guideline 201

- **NOEC (Anabaena flos-aquae):** 0.44 mg/l  
- **Exposure time:** 72 h  
- **Method:** OECD Test Guideline 201

### M-Factor (Acute aquatic toxicity)

- **M-Factor:** 1

#### Toxicity to microorganisms

- **EC50:** > 1,000 mg/l  
- **Exposure time:** 3 h  
- **Test Type:** Respiration inhibition  
- **Method:** OECD Test Guideline 209

- **NOEC:** 1,000 mg/l  
- **Exposure time:** 3 h  
- **Test Type:** Respiration inhibition  
- **Method:** OECD Test Guideline 209

#### Toxicity to fish (Chronic toxicity)

- **NOEC:** 10,6 mg/l  
- **Exposure time:** 32 d  
- **Species:** Pimephales promelas (fathead minnow)  
- **Method:** OECD Test Guideline 210

#### Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)

- **NOEC:** 9.6 mg/l  
- **Exposure time:** 21 d  
- **Species:** Daphnia magna (Water flea)  
- **Method:** OECD Test Guideline 211

### 12.2 Persistence and degradability

#### Components:

**Ceftolozane:**

- **Biodegradability:** Result: Not readily biodegradable.  
  **Method:** OECD Test Guideline 301D

**Tazobactam:**

- **Biodegradability:** Result: Not readily biodegradable.  
  **Method:** OECD Test Guideline 301D
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ceftolozane / Tazobactam Injection Formula-
tion

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4</td>
<td>12.10.2021</td>
<td>441472-00015</td>
<td>23.03.2020</td>
<td>06.01.2016</td>
</tr>
</tbody>
</table>

12.3 Bioaccumulative potential

**Components:**

**Ceftolozane:**
Partition coefficient: n-octanol/water: log Pow: -0.21

**Tazobactam:**
Partition coefficient: n-octanol/water: log Pow: -0.63

12.4 Mobility in soil

**Components:**

**Ceftolozane:**
Distribution among environmental compartments: log Koc: 3.3
Method: OECD Test Guideline 106

**Tazobactam:**
Distribution among environmental compartments: log Koc: 0.87

12.5 Results of PBT and vPvB assessment

**Product:**
Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

**Product:**
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product:**
Assessment: Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>UN 3077</td>
<td>UN 3077</td>
<td>UN 3077</td>
<td>UN 3077</td>
<td>UN 3077</td>
</tr>
</tbody>
</table>

14.2 UN proper shipping name

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ceftolozane, Tazobactam)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ceftolozane, Tazobactam)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ceftolozane, Tazobactam)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ceftolozane, Tazobactam)</td>
<td>Environmentally hazardous substance, solid, n.o.s. (Ceftolozane, Tazobactam)</td>
</tr>
</tbody>
</table>

14.3 Transport hazard class(es)

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
</tr>
</tbody>
</table>

14.4 Packing group

<table>
<thead>
<tr>
<th></th>
<th>ADN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Packing group</td>
<td>III</td>
</tr>
<tr>
<td>Classification Code</td>
<td>M7</td>
</tr>
<tr>
<td>Hazard Identification Number</td>
<td>90</td>
</tr>
<tr>
<td>Labels</td>
<td>9</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ceftolozane / Tazobactam Injection Formulation

Version 4.4 Revision Date: 12.10.2021 SDS Number: 441472-00015 Date of last issue: 23.03.2020

Date of first issue: 06.01.2016

ADR
Packing group: III
Classification Code: M7
Hazard Identification Number: 90
Labels: 9
Tunnel restriction code: (-)

RID
Packing group: III
Classification Code: M7
Hazard Identification Number: 90
Labels: 9

IMDG
Packing group: III
Labels: 9
EmS Code: F-A, S-F

IATA (Cargo)
Packing instruction (cargo aircraft): 956
Packing instruction (LQ): Y956
Packing group: III
Labels: Miscellaneous

IATA (Passenger)
Packing instruction (passenger aircraft): 956
Packing instruction (LQ): Y956
Packing group: III
Labels: Miscellaneous

14.5 Environmental hazards

ADN
Environmentally hazardous: yes

ADR
Environmentally hazardous: yes

RID
Environmentally hazardous: yes

IMDG
Marine pollutant: yes

IATA (Passenger)
Environmentally hazardous: yes

IATA (Cargo)
Environmentally hazardous: yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ceftolozane / Tazobactam Injection Formulation

Version 4.4  Revision Date: 12.10.2021  SDS Number: 441472-00015  Date of last issue: 23.03.2020
Date of first issue: 06.01.2016

14.7 Maritime transport in bulk according to IMO instruments
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

<table>
<thead>
<tr>
<th>E1</th>
<th>ENVIRONMENTAL HAZARDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quantity 1</td>
<td>Quantity 2</td>
</tr>
<tr>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

Other regulations:
Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ceftolozane / Tazobactam Injection Formula-
tion

Version 4.4 Revision Date: 12.10.2021 SDS Number: 441472-00015 Date of last issue: 23.03.2020

Date of first issue: 06.01.2016

H373 : May cause damage to organs through prolonged or repeated exposure.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.
H411 : Toxic to aquatic life with long lasting effects.

Full text of other abbreviations
Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Resp. Sens. : Respiratory sensitisation
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Classification of the mixture:
Resp. Sens. 1 H334

Classification procedure: Calculation method

20 / 21
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ceftolozane / Tazobactam Injection Formula-
tion

Version 4.4   Revision Date: 12.10.2021   SDS Number: 441472-00015   Date of last issue: 23.03.2020
Date of first issue: 06.01.2016

STOT RE 2    H373    Calculation method
Aquatic Acute 1    H400    Calculation method
Aquatic Chronic 1    H410    Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NO / EN